Prof Research published a new report on the dofetilide market. It presents the largest 8 manufacturers in the dofetilide market. The report is a professional and in-depth study on the current state of the global Dofetilide market. The report provides key statistics on the market of dofetilide. It is a valuable source of guidance and direction for companies and individuals interested in the dofetilide industry.

The global Dofetilide market was valued to be 39.72 million USD in 2020. The Dofetilide production value is anticipated to have grown with a CAGR of 24% in the coming years to reach 144.44 million USD in 2026.

Bionpharma is the largest manufacturer of Dofetilide in the world, it has a market share of 32.00% in value. Launched in 2014, Bionpharma’s goals are to develop and commercialize affordable quality generics and building strong and effective partnerships.

Aurobindo is the second-largest manufacturer of Dofetilide in the world, it has a market share of 17.90% in value. Aurobindo Pharma Limited is an Indian pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, antiretrovirals, cardiovascular, central nervous system, gastroenterological, anti-allergies and anti-diabetics.

Sigmapharm Laboratories is the third-largest manufacturer of Dofetilide in the world, it has a market share of 11.65% in value. Sigmapharm Laboratories, LLC, a privately-held specialty pharmaceutical company, develops, manufactures and markets unique Generic and Branded products often unmatched by competitors.

Mayne Pharma is the fourth largest manufacturer of Dofetilide in the world, it has a market share of 11.61% in value. Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing branded and generic pharmaceuticals. It operates through four segments: Generic Products (GPD), Specialty Brands (SBD), Metrics Contract Services (MCS) and Mayne Pharma International (MPI).